Estrogen: The Current Status and the Future Role in Postconditioning Protection to the Heart

Fawzi A Babiker*
Department of Physiology, Faculty of Medicine, Kuwait University, Kuwait

*Corresponding author: Fawzi A Babiker, Department of Physiology, Faculty of Medicine, Kuwait University, B. O. Box 24923 Safat, 13110 Kuwait

Received: September 15, 2014; Accepted: October 15, 2014; Published: October 16, 2014

Abstract

Ischemic Heart Disease (IHD) is one of the leading causes of worldwide morbidity and mortality. Reperfusion was the first procedure used to rescue the ischemic heart; however, this procedure is associated with subsequent reperfusion injury. Ischemic Preconditioning (IPC) was introduced as an intervention to protect against the potential injury before the insult occurred. Yet, the application of IPC in the clinic was limited because the onset of ischemia is not predictable and neither was the amount of damage caused by the event. Thus, Ischemic Postconditioning (IPOC) was introduced as an intervention immediately following reperfusion in order to surpass the shortcomings of preconditioning translation in the clinic. Several methods and procedures were used in postconditioning, among them are postconditioning with estrogen (17-β estradiol (E2)) and Selective E2 Receptors Modulators (SERMs). However, the role of E2 is controversial and its research was challenged by the unexpected outcomes of two large clinical trials (heart and Oestrogen/progestin Replacement Study (HERS) and Women’s Health Initiative (WHI)). Controversy still exists regarding the results of the experiments using E2; however, many scientists still believe that the potentials of E2 are yet to be unraveled. The aim of this review is to highlight the use and effects of E2 in postconditioning, as well as its possible use in future clinical research.

Keywords: Oestrogen/postconditioning; Ischemic heart disease; Ischemic preconditioning; selective estrogen receptors modulators

Introduction

Ischemic heart disease (IHD) is known to be the leading cause of death in industrialized countries and among the leading causes of morbidity and mortality worldwide [1]. The prognosis of IHD is always running hand in hand with the size of the infarcted area. Indeed, big infarcts are associated with poor prognosis and mortality [2,3]. The first procedure introduced to protect the heart from ischemic injury is reperfusion, which is the reintroduction of blood to the ischemic part of the heart. However, this method of intervention adds to the ischemic damage by causing reperfusion injury [4]. Nevertheless, this method was the only way out for heart protection in the clinic for a long period of time. Various developments in the protective regimen of reperfusion were introduced within the past decades. Several drugs were used as pharmacological treatments to assist reperfusion and to decrease Ischemic Reperfusion (I/R) injury [5].

After the use of reperfusion with its various methods for quite some time, Murry et al. [6] introduced a new procedure of heart protection targeting I/R injury. In this procedure they showed that the heart is likely protected from I/R damage if it is challenged with brief, repetitive, ischemia before the major potentially lethal ischemic event. This technique was later called Ischemic Preconditioning (IPC), which is a repetitive ischemia reperfusion before the major ischemic insult. The protection by the IPC was shown to occur at two different time points, later named windows of protection. One of these is a very short window of 1-3 hours immediately after the IPC intervention, during which any ischemic challenge can be tolerated. The second window starts 12-24 hours IPC and lasts for 2-3 days [7].

Unfortunately, this method of protection cannot be translated in the clinic due to the lack of determination of ischemic attack onset in a healthy population. However, this method could be applied in coronary or cardiac surgery where the ischemia is expected [8,9]. Preconditioning was intensely studied to unravel the underlying mechanisms, which might be used in the protection of the heart against I/R injury. The studies done on its triggers, downstream effectors, and pathways formed the first building blocks for the future methods of heart protection against IHD. About two decades after the discovery of preconditioning, another novel technique of protection was introduced by Vinten Johansen’s group which is repeated episodes of ischemia immediately at the beginning of reperfusion [10]. This procedure resulted in a protection similar to that obtained by IPC and was named Ischemic Postconditioning (IPOC) as it is applied after the ischemic insult [10].

Recently, it has been shown that acute treatment with estrogen (17-β estradiol (E2)) protects the heart against I/R injury [11]. However, in vivo long-term E2 treatment before ischemia did not show any protection against I/R injury [12]. Although the cardioprotective effects of E2 Replacement Therapy (ERT) are still controversial [13,14]; E2 pharmacological treatment in preconditioning was found to be feasible in different species [15,16] and in humans [17]. Some researchers, in an attempt to avoid the controversy and the discrepancy shown in the use of E2 started to use Selective Estrogen Receptors Modulators (SERMs). The phytoestrogen genistein was shown to protect the heart against IHD when applied at the beginning of reperfusion [18]. The research on E2 in postconditioning seems
Estrogen as a Hormone and a Therapeutic Drug

However, a lot of controversy exists in E2 studies, significant gender differences were elucidated in basic cardiovascular functions [30]. Many experimental animal studies demonstrated presence of a better papillary muscle shortening in the female rats compared to males [31]. These notions were supported by clinical studies that showed a greater myocardial and left ventricle chamber functions in women compared to men [32]. Furthermore, a higher mass-to-volume ratio was reported in men, showing a higher myocardial mass in men compared to women [33]. These gender differences shown in heart functions are mediated by E2. However, some studies reported a lack of influence of E2 decrease or withdrawal on heart functions [34]. In contrast, a significant fall in aortic peak flow velocity, mean aortic acceleration time, ejection fraction, fractional shortening and ventricular mass was demonstrated after E2 hormone withdrawal [35]. Gender also imposes evident influences on the vascular homeostasis, demonstrated by a higher arterial compliance in women compared to men [36]. Estrogen is also known to reduce arterial collagen and stiffness resulting in a more distensible blood vessel [37]. Interestingly, impairment of endothelium-dependent vasorelaxation induced by atherosclerosis was proved to be gender dependent, with females showing a better relaxation than males [38]. However, some other hormones are involved [39,40], there is a strong evidence that suggests protective effects for E2 against cardiac hypertrophy [41]. Presence of E2 was proven to abrogate and its deficiency potentiates, the development of left ventricular hypertrophy [42]. Indeed, a rapid induction of LV hypertrophy was reported in men compared to women [43]. In a previous study we also demonstrated blockade of LVH. By a pathway involving atrial natriuretic peptide [44].

Ischemic heart disease is one of the key inducers of heart failure, therefore its control is essential in the regression of disease. Estrogen was reported to play a protective role against this serious disease [45]. Observational studies demonstrated an inverse relationship between E2 use and myocardial infarction and death from ischemic heart disease [46,47]. Administration of E2 prevented ischemic [48] and reperfusion [49] arrhythmias and reduced infarct size [50]. Importantly, E2 also increased distal coronary perfusion and other hemodynamic functions of the heart during reperfusion [50]. Use of exogenous E2 by postmenopausal women, significantly decreased myocardial infarction, heart failure and the morbidity and mortality following IHD [51]. In experimental animal models of I/R, E2 was shown to improve coronary artery dilation and spare the myocardium [50].

Mechanisms of E2 Signaling in Pre- and Postconditioning

The controversy that exists in the knowledge of E2 pathways and their protective role in the cardiovascular system dictates the importance of the E2 research. The presence of E2 throughout a long period of time (premenopause) and its absence during a considerable period (postmenopause) in females, necessitates the investigation of the effects of its presence and withdrawal on the outcome of diseases, their control, and treatment. Pre- and postconditioning, as very important methods of protection against IHD, require significant knowledge of E2 influence in order to incorporate their...
use in the clinic. Estrogen, in its protective role against heart disease, is believed to function by genomic and non-genomic pathways [35]. Genomic transduction pathways of E2 are mediated by the classical E2 receptors (ERs) alpha (ERα) and beta (ERβ) [35]. These pathways are usually of slow effect, requiring time ranging from minutes to hours [52]. However, non-genomic actions of E2 are mediated by membrane ERs through a G protein-coupled receptor and do not require gene transcription [53-55]. These non-genomic pathways of E2 are involved in rapid vasodilatation [56], inhibition of vessel injury [57] and reduction of I/R injury [58]. Recently a G protein-coupled receptor 30 (GPER30) was shown to bind E2 and cause protection via non-genomic signaling [59,60].

Although the mechanisms of protection of preconditioning and postconditioning are not completely understood, both seem to follow the same signaling pathways resulting in protection [20,61]. Preconditioning and postconditioning depend mainly on the instant regulation of specific elements, which activate other downstream elements or the final effectors ending in protection [62,63]. However, their individual methods and times of application are completely different occurring either before or after the insult respectively [20,61]. Up to date the most important components of the protection pathways known today include adenosine (A1) [64,65] and angiotensin II (AT1) receptors [66]; opening of Mitochondrial Potassium mito KATP channel [67,68] and sarcosomal potassium (sarc KATP) [20] channels; activation of protein kinase C (PKC) [69,70] and PI3K-Akt [69,71,72]; prevention of the opening of the mPTP [71,73,74]; production of ROS [75,76]; and induction of NO [77,78] (Figure 1 and Table 1). However, the arrangement of these components within signaling cascades is not completely understood.

Interestingly, E2 protects the heart via cell signaling events similar to those of the classical pre- and postconditioning (Figure 1 and Table 1). In E2 preconditioning and postconditioning the pathways of protection are likely of non-genomic nature, which happens immediately after acute application of E2. Among these protective non-genomic effects are the antioxidant effect of E2 [79], inhibition of L-type Ca2+ channels [80] and PI3K-Akt [69,71,72]; prevention of the opening of the mPTP [71,73,74]; production of ROS [75,76]; and induction of NO [77,78] (Figure 1 and Table 1). However, the arrangement of these components within signaling cascades is not completely understood.

Non-genomic pathways of E2 are similar to the potential pathways of pre- and postconditioning. From this, one could speculate that E2, via similar pathways to pre- and postconditioning, will at least not compromise their effects. Acute presence or treatment with E2, via similar pathways to pre- and postconditioning, will at least encourage its use in clinical studies.

**E2 in preconditioning**

The presence of E2 is essential for the protection of the myocardium against I/R injury due to the premenopausal female myocardium being shown to be more resistant to I/R injury compared to male myocardium [91]. E2 was proven to be very effective in decreasing myocardial infarction (MI) when applied before the ischemic period

---

**Table 1:** Components or elements which were known for a given protection method. Lines indicate that the component is not studied in the given method.

<table>
<thead>
<tr>
<th>Element</th>
<th>Preconditioning</th>
<th>Postconditioning</th>
<th>E2 treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarc KATP</td>
<td>Gross GJ and Fryer RM 1999</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NO</td>
<td>Sasaki N et al [85]</td>
<td>Krolkowski JG et al [77]</td>
<td>Hisamoto K [86]</td>
</tr>
<tr>
<td>A1</td>
<td>Solenkova NV et al, [65]</td>
<td>Philipp S et al, [64]</td>
<td></td>
</tr>
<tr>
<td>Microtubules</td>
<td>Nakamura Y et al [70]</td>
<td>Babiker FA, [20]</td>
<td></td>
</tr>
<tr>
<td>AT1</td>
<td>Saito M et al [66]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ER</td>
<td></td>
<td></td>
<td>Vernehn ND et al, [114]</td>
</tr>
<tr>
<td>mPTP</td>
<td>Bopassa JC et al [74]</td>
<td>Argaud L et al [73]</td>
<td>Parkash J, [90]</td>
</tr>
<tr>
<td>GPER30</td>
<td></td>
<td></td>
<td>Noel SD, et al, [59]</td>
</tr>
</tbody>
</table>

---

**Figure 1:** Schematic representation showing the potential pathways for preconditioning, postconditioning and estrogen treatment. Dashed lines showed pathways which were not known in estrogen treatment.

---

**Abbreviations:** ER: Estrogen Receptor; A1: Adenosine Receptor 1; AT1: Angiotensin Receptor 1; TK: Tyrosine Kinase; SAC: Stretch Activated Channel.
E2 in postconditioning

If postconditioning is to be considered for clinical use, several aspects of E2 must be investigated such as the availability based on gender, short and long-term treatments with E2, and the effects of E2 withdrawal. Up to date the use of E2 in postconditioning of the myocardium is rarely considered. Only a single study considered E2 in postconditioning of the heart [108]. However, postconditioning with E2 treatment was used frequently in the protection of other organs. Estrogen postconditioning was shown to be protective in gastric epithelial cells [109,110], in neurons [111] and the mesentery [112]. Some studies manipulating individual receptors such as ERβ [113], ERα [114] and GPR30 [74] showed a protective postconditioning and simultaneously suggested a protective role for E2 in postconditioning. The fast development within postconditioning research suggests an important role in the protection against IHD. Therefore, its translation to the clinic might gain significant interest in the near future. Thus, the knowledge of the effects of the presence of E2 and the consequences of its direct use will be of vital importance for intervention in both male and female patients. Understanding gender differences in postconditioning will lead to the successful introduction of suitable methods and techniques in the clinic. Furthermore, the difference in the nature of the short and long-term E2 treatments is to be dissected for selection of the protective and less harmful treatments.

Use of SERMs in pre- and postconditioning

The risk of E2 use and its possible exacerbation of the risks of breast and endometrial cancer, venous thromboembolism [115,116] along with the discouraging results of HERS and WHI [101-103], sparked a remarkable interest in the use of Selective Estrogen Receptors Modulators (SERMs) for heart protection. This was strengthened by the observation of a decreased prevalence of IHD in populations who consume phytoestrogen [117]. Indeed this indicates that not only E2, but other related SERMs can give similar protective effects. SERMs gained popularity over E2 because of their reduced risk on the body. SERMs possess tissue specific agonist/antagonist effects [102] compared to E2, which could be beneficial for some tissues while detrimental to others [13,99,118]. They mainly act as E2 agonists on the heart and antagonists in the breast and uterus [119]. Furthermore, they can be administered safely to both sexes without any deleterious effects [102,120]. In fact, there are many known SERMs which are cardioprotective and lack the adverse effects of E2 [101-103]. However, every SERM has its own mechanism of action patients must be evaluated individually for its effects [103]. Among patients the potential postconditioning agents only genistein was investigated and proved to be protective in preconditioning producing protection similar to that attained by E2 [121]. Similar effects were also shown with its use as a postconditioning drug [18], Genistein, was also found to be effective in improving the hemodynamic and vascular function in animals [122] as well as in female patients [123]. The future research on SERMs will promote them to have significant consideration in postconditioning research for the treatment and prevention of IHD.

Postconditioning the human heart and the potential role of E2 and SERMs

Preconditioning has been proved to be effective in the human heart [124]. Trials of IPC on human atrial sections [125,126] and human skeletal muscles [127] showed significant protection against apoptotic and necrotic cell death. Although, many studies were done to validate the protective effects of postconditioning and to unravel its protective elements, the application of this technique in the clinic is rather limited. Few studies were done in small groups of patients. In these studies it was reported that postconditioning the heart with IPOC immediately after stenting the infarct-related artery, sustainably protected the heart from the subsequent I/R injury [128-131]. Promising results were also demonstrated in the clinical pilot studies using pharmacological postconditioning [132]. Indeed, postconditioning is a novel method of treatment which can save many lives. Its application in the clinic should be enhanced and large scale trials must be designed to determine whether this method of treatment could be introduced as an official method of treatment in the clinic [133]. Although, few studies were done on the effects of E2 in postconditioning, acute treatment with E2 was proved to protect the heart from I/R injury [16,134]. For safe application of postconditioning in the clinic the effects of presence or withdrawal of E2 as well as gender difference are to be considered. Acute pretreatment with E2 protected both male [16,17] and female [81,135] hearts in vivo and its acute presence during angioplasty made the heart more resistant to ischemia [17]. These results can encourage the use of acute E2 treatment in the clinic, which might be protective. Also it may carry the advantage of short term use which might not
have the negative effects of long term E2 use on cancer. Acute E2 treatment could also be used as treatment for male patients since the natural absence of E2 will not affect the outcome of the treatment and the short time use might not have negative health threats. SERMs with their selective nature and low affinity for ERα and high affinity for ERβ [136] can be applied in acute or long-term treatments.

Conclusion

Estrogen seems to be one of the essential remedies in protecting the heart against most of the cardiovascular diseases like cardiac hypertrophy, IHD and heart failure. These diseases are known to be a serious clinical problem in the whole world. The control of these diseases and protection of the heart against them is the aim of today’s medicine. Thus, it is very important to study the role of estrogen as a drug in targeting these diseases. Furthermore identification the role of E2 and its effects on postconditioning protection to the heart might open a new avenue in the treatment of the heart against IHD.

References


64. Philipp S, Yang XM, Cui L, Davis AM, Downey JM, Cohen MV. Postconditioning protects rabbit hearts through a protein kinase C-adenosine A2b receptor cascade. Cardiovasc Res. 2006; 70: 308-314.


72. Yang XM, Philipp S, Downey JM, Cohen MV. Postconditioning’s protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol. 2005; 100: 57-63.


100. Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation. 2001; 104: 2256-2259.


108. Crisostomo PR, Wang M, Wairiuko GM, Terrell AM, Meldrum DR.


